Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Brophy

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Nursing New Zealand (Wellington, N.Z. : 1995)|May 21, 2008
Resisting the forces of economic rationalism and managerialismSarah Brophy
Nursing New Zealand (Wellington, N.Z. : 1995)|June 2, 2006
Advancing nursing leadershipSarah Brophy
Nursing New Zealand (Wellington, N.Z. : 1995)|January 2, 2009
Making the case for case study researchSarah Brophy
Journal of Tissue Viability|July 17, 2021
What is the incidence of medical device-related pressure injuries in adults within the acute hospital setting? A systematic reviewSarah Brophy, Zena Moore, Declan Patton, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 18, 2023
Isolation and Cryopreservation of Mononuclear Cells from Peripheral Blood and Bone Marrow of Blood Cancer PatientsSarah Brophy, Rebecca Amet, Hayley Foy-Stones, et al.
Gut|March 9, 2010
Eosinophilic gastroenteritisBen Dunne, Sarah Brophy, Julian Tsang, et al.
International Journal of Cancer|July 2, 2009
GLUT-1 expression and response to chemoradiotherapy in rectal cancerSarah Brophy, Katherine M Sheehan, Deborah A McNamara, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 6, 2015
The patients' active role in managing a personal electronic health record: a qualitative analysisInes Baudendistel, Eva Winkler, Martina Kamradt, et al.
Cytotherapy|September 1, 2022
Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cellsMark Gurney, Eimear O'Reilly, Sarah Corcoran, et al.
Life Sciences|December 26, 2021
A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myelomaRebecca Amet, Viola Previtali, Helene B Mihigo, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Nursing New Zealand (Wellington, N.Z. : 1995)|May 21, 2008
Resisting the forces of economic rationalism and managerialismSarah Brophy
Nursing New Zealand (Wellington, N.Z. : 1995)|June 2, 2006
Advancing nursing leadershipSarah Brophy
Nursing New Zealand (Wellington, N.Z. : 1995)|January 2, 2009
Making the case for case study researchSarah Brophy
Journal of Tissue Viability|July 17, 2021
What is the incidence of medical device-related pressure injuries in adults within the acute hospital setting? A systematic reviewSarah Brophy, Zena Moore, Declan Patton, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 18, 2023
Isolation and Cryopreservation of Mononuclear Cells from Peripheral Blood and Bone Marrow of Blood Cancer PatientsSarah Brophy, Rebecca Amet, Hayley Foy-Stones, et al.
Gut|March 9, 2010
Eosinophilic gastroenteritisBen Dunne, Sarah Brophy, Julian Tsang, et al.
International Journal of Cancer|July 2, 2009
GLUT-1 expression and response to chemoradiotherapy in rectal cancerSarah Brophy, Katherine M Sheehan, Deborah A McNamara, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 6, 2015
The patients' active role in managing a personal electronic health record: a qualitative analysisInes Baudendistel, Eva Winkler, Martina Kamradt, et al.
Cytotherapy|September 1, 2022
Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cellsMark Gurney, Eimear O'Reilly, Sarah Corcoran, et al.
Life Sciences|December 26, 2021
A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myelomaRebecca Amet, Viola Previtali, Helene B Mihigo, et al.
Pageof 2